Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment

Nicasio Mancini, Silvia Carletti, Mario Perotti, Luisa Romanò, Rosellina Di Stefano Craxì, Antonio Craxì, Alessandro R. Zanetti, Massimo Clementi, Roberto Burioni

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The dynamic features of three specific anti-hepatitis C virus (HCV) antibody subpopulations directed against different conformational epitopes of the viral E2 protein (HCV/E2) have been evaluated in patients with primary and persistent HCV infection; the three subpopulations are present in patients infected with different HCV genotypes and have shown a different activity using a pseudovirus neutralization assay (antibodies e301 and e137 exhibiting high neutralizing activity, while antibody e509 enhancement of HCV infectivity). In sequential samples from five patients with primary HCV infection and different virological outcome, all samples tested negative with the single exception of the e509 antibody in a patient not clearing the virus. In sequential samples from 28 patients with persistent infection under treatment with pegylated interferon-α plus ribavirin (14 sustained virological responders and 14 non-responders), the therapy did not selectively influence titers of the two neutralizing antibody subpopulations; otherwise, a net increase of the e509 antibody subpopulation related to enhancement of HCV infectivity was observed in non-responders, but not in sustained virological responders (P = 0.0156). This increase was not related to the trend of total anti-HCV/E2 response. The data indicate that a specific antibody response against these epitopes is elicited only late during the infection, thus not influencing virus clearance during primary infection, and that a selective increase of the antibody subpopulation enhancing virus infectivity is observed only in the cohort of patients not responding to antiviral therapy.

Original languageEnglish
Pages (from-to)1304-1311
Number of pages8
JournalJournal of Medical Virology
Volume78
Issue number10
DOIs
Publication statusPublished - Oct 2006

Fingerprint

Hepatitis C Antibodies
Hepacivirus
Epitopes
Antibodies
Virus Diseases
Viruses
Therapeutics
Infection
Blocking Antibodies
Ribavirin
Viral Proteins
Protein C
Neutralizing Antibodies
Interferons
Antibody Formation
Antiviral Agents
Genotype

Keywords

  • Epitope-specific response
  • HCV/E2 glycoprotein
  • Human monoclonal antibodies
  • Therapeutic response

ASJC Scopus subject areas

  • Virology

Cite this

Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment. / Mancini, Nicasio; Carletti, Silvia; Perotti, Mario; Romanò, Luisa; Di Stefano Craxì, Rosellina; Craxì, Antonio; Zanetti, Alessandro R.; Clementi, Massimo; Burioni, Roberto.

In: Journal of Medical Virology, Vol. 78, No. 10, 10.2006, p. 1304-1311.

Research output: Contribution to journalArticle

Mancini, Nicasio ; Carletti, Silvia ; Perotti, Mario ; Romanò, Luisa ; Di Stefano Craxì, Rosellina ; Craxì, Antonio ; Zanetti, Alessandro R. ; Clementi, Massimo ; Burioni, Roberto. / Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment. In: Journal of Medical Virology. 2006 ; Vol. 78, No. 10. pp. 1304-1311.
@article{437c9f1f26424b91ba69876a0d6d145a,
title = "Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment",
abstract = "The dynamic features of three specific anti-hepatitis C virus (HCV) antibody subpopulations directed against different conformational epitopes of the viral E2 protein (HCV/E2) have been evaluated in patients with primary and persistent HCV infection; the three subpopulations are present in patients infected with different HCV genotypes and have shown a different activity using a pseudovirus neutralization assay (antibodies e301 and e137 exhibiting high neutralizing activity, while antibody e509 enhancement of HCV infectivity). In sequential samples from five patients with primary HCV infection and different virological outcome, all samples tested negative with the single exception of the e509 antibody in a patient not clearing the virus. In sequential samples from 28 patients with persistent infection under treatment with pegylated interferon-α plus ribavirin (14 sustained virological responders and 14 non-responders), the therapy did not selectively influence titers of the two neutralizing antibody subpopulations; otherwise, a net increase of the e509 antibody subpopulation related to enhancement of HCV infectivity was observed in non-responders, but not in sustained virological responders (P = 0.0156). This increase was not related to the trend of total anti-HCV/E2 response. The data indicate that a specific antibody response against these epitopes is elicited only late during the infection, thus not influencing virus clearance during primary infection, and that a selective increase of the antibody subpopulation enhancing virus infectivity is observed only in the cohort of patients not responding to antiviral therapy.",
keywords = "Epitope-specific response, HCV/E2 glycoprotein, Human monoclonal antibodies, Therapeutic response",
author = "Nicasio Mancini and Silvia Carletti and Mario Perotti and Luisa Roman{\`o} and {Di Stefano Crax{\`i}}, Rosellina and Antonio Crax{\`i} and Zanetti, {Alessandro R.} and Massimo Clementi and Roberto Burioni",
year = "2006",
month = "10",
doi = "10.1002/jmv.20704",
language = "English",
volume = "78",
pages = "1304--1311",
journal = "Journal of Medical Virology",
issn = "0146-6615",
publisher = "Wiley-Liss Inc.",
number = "10",

}

TY - JOUR

T1 - Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment

AU - Mancini, Nicasio

AU - Carletti, Silvia

AU - Perotti, Mario

AU - Romanò, Luisa

AU - Di Stefano Craxì, Rosellina

AU - Craxì, Antonio

AU - Zanetti, Alessandro R.

AU - Clementi, Massimo

AU - Burioni, Roberto

PY - 2006/10

Y1 - 2006/10

N2 - The dynamic features of three specific anti-hepatitis C virus (HCV) antibody subpopulations directed against different conformational epitopes of the viral E2 protein (HCV/E2) have been evaluated in patients with primary and persistent HCV infection; the three subpopulations are present in patients infected with different HCV genotypes and have shown a different activity using a pseudovirus neutralization assay (antibodies e301 and e137 exhibiting high neutralizing activity, while antibody e509 enhancement of HCV infectivity). In sequential samples from five patients with primary HCV infection and different virological outcome, all samples tested negative with the single exception of the e509 antibody in a patient not clearing the virus. In sequential samples from 28 patients with persistent infection under treatment with pegylated interferon-α plus ribavirin (14 sustained virological responders and 14 non-responders), the therapy did not selectively influence titers of the two neutralizing antibody subpopulations; otherwise, a net increase of the e509 antibody subpopulation related to enhancement of HCV infectivity was observed in non-responders, but not in sustained virological responders (P = 0.0156). This increase was not related to the trend of total anti-HCV/E2 response. The data indicate that a specific antibody response against these epitopes is elicited only late during the infection, thus not influencing virus clearance during primary infection, and that a selective increase of the antibody subpopulation enhancing virus infectivity is observed only in the cohort of patients not responding to antiviral therapy.

AB - The dynamic features of three specific anti-hepatitis C virus (HCV) antibody subpopulations directed against different conformational epitopes of the viral E2 protein (HCV/E2) have been evaluated in patients with primary and persistent HCV infection; the three subpopulations are present in patients infected with different HCV genotypes and have shown a different activity using a pseudovirus neutralization assay (antibodies e301 and e137 exhibiting high neutralizing activity, while antibody e509 enhancement of HCV infectivity). In sequential samples from five patients with primary HCV infection and different virological outcome, all samples tested negative with the single exception of the e509 antibody in a patient not clearing the virus. In sequential samples from 28 patients with persistent infection under treatment with pegylated interferon-α plus ribavirin (14 sustained virological responders and 14 non-responders), the therapy did not selectively influence titers of the two neutralizing antibody subpopulations; otherwise, a net increase of the e509 antibody subpopulation related to enhancement of HCV infectivity was observed in non-responders, but not in sustained virological responders (P = 0.0156). This increase was not related to the trend of total anti-HCV/E2 response. The data indicate that a specific antibody response against these epitopes is elicited only late during the infection, thus not influencing virus clearance during primary infection, and that a selective increase of the antibody subpopulation enhancing virus infectivity is observed only in the cohort of patients not responding to antiviral therapy.

KW - Epitope-specific response

KW - HCV/E2 glycoprotein

KW - Human monoclonal antibodies

KW - Therapeutic response

UR - http://www.scopus.com/inward/record.url?scp=33748652905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748652905&partnerID=8YFLogxK

U2 - 10.1002/jmv.20704

DO - 10.1002/jmv.20704

M3 - Article

VL - 78

SP - 1304

EP - 1311

JO - Journal of Medical Virology

JF - Journal of Medical Virology

SN - 0146-6615

IS - 10

ER -